Pleural Effusion in Mesothelioma: Drainage, Recurrence, and What It Means for Prognosis

For most people with pleural mesothelioma, the disease is identified because of fluid. Persistent shortness of breath sends someone to a clinician. A chest X-ray shows haze on one side. A thoracentesis pulls a liter of straw-colored fluid out of the chest, the patient breathes more easily for a few days, and then the fluid begins to come back. That sequence is so consistent that pleural effusion is the clinical fingerprint of pleural mesothelioma.

This guide is for people who have just had an effusion drained, or whose family member has, and want to understand what the drainage accomplishes, why it tends to recur, and how the choice between thoracentesis, indwelling catheter, and talc pleurodesis is made. It draws on the NCI Mesothelioma PDQ, the British Thoracic Society Pleural Disease Guideline, and the two large randomized trials (TIME2, AMPLE) that anchor current practice.

What Pleural Effusion Is in Mesothelioma

The pleura is a two-layer membrane: the parietal pleura lines the inside of the chest wall, the visceral pleura wraps the surface of the lung. Between them sits a thin film of lubricating fluid, normally just a few milliliters, that lets the lung slide during breathing. In pleural mesothelioma, tumor cells grow along this membrane. They thicken the pleural surface, disrupt the lymphatic drainage that normally clears fluid, and increase capillary leak from the inflamed tumor bed. The result is a malignant pleural effusion, which in mesothelioma can range from several hundred milliliters to more than two liters.

The British Thoracic Society Pleural Disease Guideline 2010 (Roberts et al., Thorax) reports that lung cancer, breast cancer, lymphoma, and mesothelioma together account for approximately 75% of all malignant pleural effusions. Robinson and Lake’s NEJM 2005 review described the typical mesothelioma presentation: “Patients usually present with dyspnoea and/or chest pain, which are frequently caused by a pleural effusion.” The effusion is what makes someone breathless, what shows up on imaging, and very often what brings someone to the thoracic team in the first place.

How It Presents

The classic triad of symptoms at presentation is shortness of breath, chest discomfort, and a dry persistent cough. The shortness of breath usually comes on gradually over weeks to months, worse with exertion. The chest discomfort is often dull, on one side, and may feel referred to the shoulder or upper back. Cough, when present, is usually nonproductive.

Each of these features is nonspecific in isolation. What pushes mesothelioma higher on the differential is the combination of unilateral effusion (almost always one side, not both), pleural thickening or pleural plaques on imaging, and a history of asbestos exposure decades earlier. Bibby et al., Lung Cancer 2016, summarized the pattern: pleural effusion is the most common presenting feature, and definitive diagnosis usually requires pleural biopsy.

Diagnosis: Thoracentesis, Cytology, and Biopsy

When a unilateral pleural effusion is found in someone with possible asbestos exposure, the diagnostic workup almost always starts with thoracentesis: a needle drainage, usually under ultrasound guidance, that both relieves symptoms and provides fluid for analysis. Pleural fluid is sent for cytology, biochemistry (protein, LDH, glucose, pH), and microbiology.

The 2018 International Mesothelioma Interest Group guidelines (Husain et al., Archives of Pathology and Laboratory Medicine) make a critical point: cytology alone is often not enough. Sensitivity is limited, particularly for sarcomatoid and biphasic histology, and a definite diagnosis generally requires histologic confirmation supported by an appropriate panel of immunohistochemical markers. In practice, most people with a strong clinical suspicion of mesothelioma will need a pleural biopsy: image-guided percutaneous biopsy or, more commonly, medical thoracoscopy or video-assisted thoracoscopic surgery (VATS), which allow direct visualization of the pleura and harvest of multiple, larger tissue samples.

Plasma and pleural-fluid biomarkers, including mesothelin and fibulin-3, have been investigated as adjuncts. Pass et al., NEJM 2012, reported that plasma fibulin-3 could distinguish people with mesothelioma from asbestos-exposed individuals without disease and from patients with non-mesothelioma effusions. Biomarkers remain adjunctive; they do not replace tissue diagnosis.

Drainage Options

Once a diagnosis is established, the question becomes how to manage the recurrent fluid. The three main options are simple thoracentesis, an indwelling pleural catheter (IPC), and chemical pleurodesis (most commonly with talc).

Simple thoracentesis

Therapeutic thoracentesis removes up to 1.5 liters of fluid in a single sitting and gives most people immediate relief from breathlessness. The downside is that the fluid almost always comes back. The BTS guideline notes that thoracentesis alone is rarely a definitive solution in malignant effusion; it is best understood as the diagnostic step that opens the door to a definitive drainage strategy.

Indwelling pleural catheter (IPC)

An IPC is a soft silicone tube placed through the chest wall under local anesthetic, with a one-way valve at the end. It stays in long-term. Drainage bottles attach to the valve at home, usually every one to three days.

Two large randomized trials anchor the current evidence:

• TIME2 (Davies et al., JAMA 2012) randomized 106 patients with malignant pleural effusion to IPC versus chest tube and talc pleurodesis. Both arms gave comparable improvement in dyspnea at 42 days, but IPC reduced initial hospital stay (median 0 days vs 4 days, p < 0.001) and reduced further pleural intervention at six months (6% vs 22%, p = 0.03).
• AMPLE (Thomas et al., JAMA 2017) randomized 146 patients to IPC versus talc pleurodesis. IPC reduced total hospitalization days from procedure to death or 12 months (median 10.0 vs 12.0 days) and reduced repeat pleural procedures (4.1% vs 22.5%).

Both trials reach the same conclusion: IPC controls the effusion at least as well as talc pleurodesis, with fewer hospital days, although infection risk (catheter-site cellulitis, occasional empyema) is real and home care is required.

Talc pleurodesis

Pleurodesis is the deliberate creation of an inflammatory adhesion between the visceral and parietal pleura, sealing the space so fluid cannot accumulate. Talc is the most widely used sclerosing agent. It is delivered as a slurry through a chest tube or as a poudrage at thoracoscopy. The Dresler et al., Chest 2005 multicenter randomized trial compared the two delivery methods and found similar overall pleurodesis success at 30 days. The choice between methods is driven more by what is operationally available at a given center than by clear superiority of one approach.

The harder problem is that pleurodesis depends on the lung re-expanding to touch the chest wall. In mesothelioma, the encasing growth of tumor along the visceral pleura often prevents that re-expansion. The BTS guideline puts it directly: “successful pleurodesis depends on apposition of the visceral and parietal pleura. A trapped lung, often seen in mesothelioma, prevents this.” That is the central reason pleurodesis fails more often in mesothelioma than in effusions from breast or lung primaries.

What Recurrence Means

For people who had a thoracentesis without a definitive drainage strategy, the question of recurrence is not really if but when. The BTS guideline is explicit that thoracentesis alone is rarely definitive in malignant effusion, because the underlying tumor continues to drive fluid production and impair lymphatic clearance.

After pleurodesis, recurrence usually means one of two things: the lung never fully re-expanded, or the tumor has progressed to a point where it overcomes the adhesion. Either way, recurrence after pleurodesis tends to prompt placement of an IPC.

After IPC placement, recurrence in the strict sense is uncommon, because the catheter continues to drain fluid as it forms. What can happen with an IPC is auto-pleurodesis: chronic mild irritation from the draining catheter produces a spontaneous pleural adhesion in roughly a quarter to a third of patients, after which fluid stops re-accumulating and the catheter can be removed. Both TIME2 and AMPLE documented this. It is one reason IPCs are increasingly favored as a first-line definitive option in mesothelioma.

Prognostic Implications

A malignant pleural effusion is itself a marker that the disease is at least locally advanced. Beyond that, the prognostic signals from the effusion are nuanced.

Two scoring systems remain widely cited:

• The EORTC prognostic score (Curran et al., J Clin Oncol, 1998) combines performance status, white blood cell count, histology, gender, and certainty of diagnosis to stratify patients into good and poor prognosis groups.
• The CALGB prognostic system (Herndon et al., Chest, 1998) identified performance status, age, weight loss, chest pain, platelet count, hemoglobin, and histology as independent prognostic factors in 337 patients.

Neither system uses pleural fluid volume as a prognostic input. The clinical signal in modern practice is less about the fluid itself and more about how the patient does after definitive drainage: does the lung re-expand, does dyspnea resolve, does the patient regain enough performance status to tolerate systemic therapy? Those answers shape prognosis more than the volume of fluid removed.

The CheckMate-743 trial (Baas et al., Lancet 2021) demonstrated that first-line nivolumab plus ipilimumab improved overall survival compared with platinum-based chemotherapy in unresectable pleural mesothelioma (median 18.1 vs 14.1 months; HR 0.74), establishing combination immunotherapy as a standard first-line option. The trial did not report pleural effusion outcomes or drainage frequency, so any claim that immunotherapy reduces the need for repeat drainage sits outside the published evidence.

What This Means for Patients and Families

Three practical points come out of the primary literature.

First, an effusion is almost always part of the picture. By the time pleural mesothelioma is diagnosed, fluid in the chest is the most consistent imaging finding and the main driver of symptoms.

Second, the choice between IPC and pleurodesis turns on lung re-expansion. If the lung re-expands fully after drainage, talc pleurodesis is reasonable. If it does not, an IPC is generally the better option. That decision is made by the thoracic team after looking at the post-drainage chest film.

Third, the trial-level evidence (TIME2, AMPLE) shows IPCs reduce hospital days and repeat procedures compared with talc pleurodesis, with infection risk that is real but manageable. In mesothelioma specifically, where trapped lung is more common, IPCs have steadily moved toward being the preferred first-line definitive option in many specialist programs. The surgical and pulmonary leads who manage these decisions, including Dr. Raphael Bueno at Brigham and Women’s Hospital, are the people whose published guidance, alongside the NCI Mesothelioma PDQ and the BTS guideline, anchors current practice. The drainage decision shapes hospital days, treatment options, and quality of life for the months that follow.

Frequently Asked Questions